Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML

Prof Naval Daver - MD Anderson Cancer Center, Houston, USA
Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML ( Prof Naval Daver - MD Anderson Cancer Center, Houston, USA )
24 Jun 2017

Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia

Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK
Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia ( Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK )
24 Jun 2017

Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia

Dr Max Topp - University of Wurzburg, Wurzburg, Germany
Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )
24 Jun 2017

TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL

Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA
TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL ( Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA )
24 Jun 2017

FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma

Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany
FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma ( Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany )
24 Jun 2017

Interim analysis of the JULIET study

Prof Gilles Salles - Université Claude Bernard, Lyon, France
Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )
24 Jun 2017

ZUMA1 trial of CD19 CAR T cells for aggressive NHL

Dr Yi Lin - Mayo Clinic, Rochester, USA
ZUMA1 trial of CD19 CAR T cells for aggressive NHL ( Dr Yi Lin - Mayo Clinic, Rochester, USA )
24 Jun 2017

Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL

Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017

European guidelines for breast cancer treatment

Dr Ciarán Nicholl - Research Centre Ispra, European Commission, Belgium
European guidelines for breast cancer treatment ( Dr Ciarán Nicholl - Research Centre Ispra, European Commission, Belgium )
19 Jun 2017

ESMO ranking of the clinical benefits of new drugs

Prof Alberto Sobrero - Ospedale San Martino, Genova, Italy
ESMO ranking of the clinical benefits of new drugs ( Prof Alberto Sobrero - Ospedale San Martino, Genova, Italy )
19 Jun 2017

Europa Uomo - improving prostate cancer patients quality of life across Europe

Prof Louis Denis - Europa Uomo, Belgium
Europa Uomo - improving prostate cancer patients quality of life across Europe ( Prof Louis Denis - Europa Uomo, Belgium )
19 Jun 2017

Personalised medicine for rare cancers

Prof Paolo Casali - Università degli Studi di Milano, Milan, Italy
Personalised medicine for rare cancers ( Prof Paolo Casali - Università degli Studi di Milano, Milan, Italy )
19 Jun 2017